Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Diabesity: an overview of a rising epidemic.Nephrol Dialysis Transplant. 2011; 26 (Accessed October 2017.): 28-35
National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. https://www.nice.org.uk/guidance/ng28. Accessed October 2017.
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.Lancet. 2010; 375 (https://www.ncbi.nlm.nih.gov/pubmed/20609967. Accessed October 2017): 2215-2222
- Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.Clin Med Insights Endocrinol Diabetes. 2015; 8 (Accessed October 2017.): 13-19
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia. 2012; 55: 1577-1596
- Standards of medical care in diabetes--2015: summary of revisions.Diabetes Care. 2015; 38 (Accessed October 2017.): S4
- Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.Drugs. 2010; 70: 377-385
- Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Diabetes Care. 2012; 35: 1232-1238
- Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.J Clin Endocrinol Metab. 2013; 98: E867-E871
- PRFORXIGA® [product monograph].AstraZeneca Canada Inc, Mississauga, ON2016
- PrINVOKAMET® [product monograph].Janssen, Inc, Raritan, NJ2017
- PrJARDIANCE™ [product monograph].Boehringer Ingelheim (Canada) Ltd, Burlington, ONJanuary 9, 2017
US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed June 1, 2017.
European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500202388.pdf. Accessed October 2017
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Diabetes Obes Metab. 2013; 15: 372-382
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.Lancet. 2013; 382: 941-950
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes Obes Metab. 2012; 14: 539-545
- Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.Diabetes Ther. 2016; 7 (Accessed October 2017.): 659-678
- Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.Diabetes Obes Metab. 2017; 19: 387-393
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.Diabetes Ther. 2015; 6 (Accessed October 2017.): 289-302
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.Int J Clin Pract. 2013; 67: 1267-1282
- Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.Diabetes Ther. 2014; 5 (Accessed October 2017.): 267-283
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.N Engl J Med. 2017; 377 (Accessed October 2017.): 644-657